- Home
- TECX vs AAM Comparison
TECX vs AAM Comparison
Compare TECX & AAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- AAM
- Stock Information
- Founded
- TECX 2019
- AAM 2024
- Country
- TECX United States
- AAM United States
- Employees
- TECX N/A
- AAM N/A
- Industry
- TECX
- AAM
- Sector
- TECX
- AAM
- Exchange
- TECX Nasdaq
- AAM Nasdaq
- Market Cap
- TECX 387.1M
- AAM 460.0M
- IPO Year
- TECX 2018
- AAM 2024
- Fundamental
- Price
- TECX $23.51
- AAM $10.45
- Analyst Decision
- TECX Strong Buy
- AAM
- Analyst Count
- TECX 5
- AAM 0
- Target Price
- TECX $79.00
- AAM N/A
- AVG Volume (30 Days)
- TECX 230.2K
- AAM 65.7K
- Earning Date
- TECX 08-07-2025
- AAM 01-01-0001
- Dividend Yield
- TECX N/A
- AAM N/A
- EPS Growth
- TECX N/A
- AAM N/A
- EPS
- TECX N/A
- AAM 0.32
- Revenue
- TECX N/A
- AAM N/A
- Revenue This Year
- TECX N/A
- AAM N/A
- Revenue Next Year
- TECX N/A
- AAM N/A
- P/E Ratio
- TECX N/A
- AAM $32.54
- Revenue Growth
- TECX N/A
- AAM N/A
- 52 Week Low
- TECX $13.70
- AAM $9.96
- 52 Week High
- TECX $61.07
- AAM $10.79
- Technical
- Relative Strength Index (RSI)
- TECX 56.50
- AAM N/A
- Support Level
- TECX $21.31
- AAM N/A
- Resistance Level
- TECX $23.12
- AAM N/A
- Average True Range (ATR)
- TECX 1.53
- AAM 0.00
- MACD
- TECX 0.13
- AAM 0.00
- Stochastic Oscillator
- TECX 71.85
- AAM 0.00
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
About AAM AA Mission Acquisition Corp. Class A Ordinary Shares
AA Mission Acquisition Corp is a blank check company.